Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | NAT1 |
| Gene Name: | NAT1 |
| Protein Full Name: | Arylamine N-acetyltransferase 1 |
| Alias: | AAC1; ARY1; ARY2; Arylamide acetylase 1; Arylamine N-acetyltransferase; MNAT; Monomorphic arylamine N-acetyltransferase; N-acetyltransferase 1 |
| Mass (Da): | 33900 |
| Number AA: | 290 |
| UniProt ID: | P18440 |
| Locus ID: | 9 |
| COSMIC ID: | NAT1 |
| Gene location on chromosome: | 8p22 |
| Cancer protein type: | UNCLEAR |
| Effect of cancer mutation on protein: | UNCLEAR |
| Effect of active protein on cancer: | MIXED |
| Number of cancer specimens: | 19625 |
| Percent of cancer specimens with mutations: | 0.14 |
| Mutations observed as inherited: | NA |
| Found in amplified chromosomal regions in human cancers: | NA |
| Deregulated in translocations: | NA |
| Deregulated by viral insertion: | NA |
| Transduced into viral genome: | NA |
| Gene undergoes hypermethylation: | NA |
| Normal role description: | NAT1 is an arylamide acetylase that participates in the detoxification of multiple drugs such as hydrazine and arylamine, and may also activate several known carcinogens. Defects in the protein alter its activity - particularly, slow acetylation genotypes have been associated with increased lung cancer risk. |